2023
Creating a Longitudinal HCV Care Cascade for Persons With HIV/HCV Coinfection in Selected HIV Clinics Using Data to Care Methods
Brooks R, Wegener M, Speers S, Nichols L, Sideleau R, Valeriano T, Buchelli M, Villanueva M. Creating a Longitudinal HCV Care Cascade for Persons With HIV/HCV Coinfection in Selected HIV Clinics Using Data to Care Methods. Health Promotion Practice 2023, 24: 1039-1049. PMID: 37439600, DOI: 10.1177/15248399231169792.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHCV coinfectionHepatitis C virusSVR ratesHCV treatmentHIV clinicTreatment cascadeTreatment statusSustained virologic response ratesHCV care cascadeHCV treatment cascadeHCV treatment statusVirologic response ratesHIV viral suppressionPatient treatment statusPublic health approachCare cascadeHepatitis CViral suppressionActing antiviralsTreatment initiationC virusResponse rateClinical staffCoinfection
2021
A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment
Seaman A, King C, Kaser T, Geduldig A, Ronan W, Cook R, Chan B, Levander X, Priest K, Korthuis P. A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment. International Journal Of Drug Policy 2021, 96: 103359. PMID: 34325969, PMCID: PMC8720290, DOI: 10.1016/j.drugpo.2021.103359.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsLogistic regression modelsCascade progressionHepatitis C elimination targetsCox proportional hazards modelMultiple logistic regression modelHCV care cascadeHCV treatment cascadeSingle blood drawPresence of opioidsLikelihood of screeningProportional hazards modelTreatment of peopleHCV screeningCare cascadeHCV treatmentActing antiviralsBundle interventionsMultinomial logistic regression modelsPatient characteristicsHCV PCRTreatment cascadeTreatment initiationHomeless clinicRegression models
2015
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, Sapir D, Wright J, Eggers C, Drozd K, Ciarleglio M, Deng Y, Lim JK. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. PLOS ONE 2015, 10: e0135645. PMID: 26312999, PMCID: PMC4552165, DOI: 10.1371/journal.pone.0135645.Peer-Reviewed Original ResearchConceptsSofosbuvir/ledipasvirViral loadMedicaid coverageChild-Pugh class B diseaseInitial approvalEnd-stage liver disease (MELD) scoreStage liver disease scoreChronic HCV infectionClass B diseaseDrug authorizationHCV care cascadeSOF/LEDAdvanced liver diseaseBaseline viral loadHepatitis C infectionLiver Disease scoreRetrospective chart reviewHigh viral loadSignificant predictorsHigher likelihoodMedicare/MedicaidSOF/C infectionCare cascadeHCV infection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply